18F-Fluorodeoxyglucose-positron emission tomography/computed tomography in Lymphoma.

Authors

Akshay Bedmutha, Leen Alkukhun, Michal Weiler-Sagie, Amol Madan Takalkar

Published in

PET clinics. Aug 13, 2026. Epub Aug 13, 2026.

Abstract

FDG-PET/CT is central to Lugano-based staging, Deauville-scored response assessment, and prognostication across Hodgkin and non-Hodgkin lymphoma subtypes. Quantitative metrics, particularly total metabolic tumor volume, have emerged as powerful independent prognostic biomarkers. In Hodgkin's lymphoma, interim PET successfully guides treatment de-escalation, while in DLBCL, interim PET remains prognostic but not therapeutically actionable. FDG-PET/Ct is a valuable prognostic biomarker for multi-time point assessment during CAR-T therapy, and guides bridging therapy. More sophisticated PET prognostic and response assessment criteria are emerging in the era of targeted therapies with the help of PET radiomics and deep learning, which needs standardization.

PMID:
42595627
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.